<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="131285">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02097277</url>
  </required_header>
  <id_info>
    <org_study_id>MB130-002</org_study_id>
    <nct_id>NCT02097277</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate BMS-986036 in Obese Adults With Type-2 Diabetes</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multiple Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Effects of BMS-986036 in Obese Adults With Type-2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <authority>Canada: Health Canada</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the potential of BMS-986036 for treatment obese
      adults with type-2 diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">August 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in glycosylated hemoglobin A1c (HbA1c) from baseline to Week 12</measure>
    <time_frame>Baseline (Day 1)  and Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessments will be based on medical review of adverse event reports and the results of vital sign measurements, Electrocardiogram (ECGs), physical examinations and clinical laboratory tests</measure>
    <time_frame>Up to 161 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average concentration (Cavg) of BMS-986036</measure>
    <time_frame>13 time points up to 126 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough observed concentration (Cmin) of BMS-986036</measure>
    <time_frame>13 time points up to 126 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed concentration (Cmax) of BMS-986036</measure>
    <time_frame>13 time points up to 126 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve (AUC) at steady state of BMS-986036</measure>
    <time_frame>13 time points up to 126 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change or percent change in Body weight, Waist circumference and Body mass index (BMI) from baseline to Week 12</measure>
    <time_frame>Baseline (Day 1) and Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change or percent change in Insulin sensitivity indexes, calculated from Glucose and Insulin in oral glucose tolerance test (OGTT), from baseline to Week 12</measure>
    <time_frame>Baseline (Day 1) and Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Insulin sensitivity index include Homeostatic model assessment of Insulin resistance (HOMA-IR), Quantitative Insulin sensitivity check index (QUICKI) and Matsuda Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change or percent change in OGTT area under the curve from 0 to 120 minutes for postprandial glucose and Insulin response to an OGTT from baseline to Week 12</measure>
    <time_frame>Baseline (Day 1) and Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change or percent change in fasting Plasma glucose, Serum Insulin and Serum C-peptide from baseline to Week 12</measure>
    <time_frame>Baseline (Day 1) and Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity measures</measure>
    <time_frame>Up to 161 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Subjects will be monitored for antibodies to study medication and to FGF-21 with an anti-drug antibody assay and an anti-FGF21 assay. Titers will be reported for samples testing positive in either assay. In addition, subjects testing positive in either assay will be assessed for neutralizing antibodies with a functional cell based neutralizing antibody assay</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Diabetes Mellitus Type 2</condition>
  <arm_group>
    <arm_group_label>Treatment A: Placebo (Matching with BMS-986036 - Daily)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (Matching with BMS-986036) 0 mg subcutaneous injection once daily  for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: Treatment B: BMS-986036 (1 mg Daily)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986036 1 mg subcutaneous injection once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C: BMS-986036 (5 mg Daily)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986036 5 mg subcutaneous injection once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment D: BMS-986036 (20 mg Daily)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986036 20 mg subcutaneous injection once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment E: BMS-986036 (20 mg Weekly)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986036 20 mg subcutaneous injection once weekly (on Day 1 of each week) for 12 weeks
Followed by Placebo (Matching with BMS-986036) 0 mg subcutaneous injection on Days 2-7 of each week for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BMS-986036</intervention_name>
    <arm_group_label>Arm 2: Treatment B: BMS-986036 (1 mg Daily)</arm_group_label>
    <arm_group_label>Treatment C: BMS-986036 (5 mg Daily)</arm_group_label>
    <arm_group_label>Treatment D: BMS-986036 (20 mg Daily)</arm_group_label>
    <arm_group_label>Treatment E: BMS-986036 (20 mg Weekly)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo (Matching with BMS-986036)</intervention_name>
    <arm_group_label>Treatment A: Placebo (Matching with BMS-986036 - Daily)</arm_group_label>
    <arm_group_label>Treatment E: BMS-986036 (20 mg Weekly)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Diagnosed with type-2 diabetes mellitus with HbA1c &gt;7.0% to less than 10.0%

          -  Body mass index 30.0 to 40.0

        Exclusion Criteria:

          -  Any significant acute or chronic medical illness

          -  Inability to self-administer subcutaneous injections

          -  Inability to be venipunctured

          -  Evidence of organ dysfunction beyond what is consistent with the target population

          -  History of allergy to PEGylated compounds or Fibroblast growth factor 21 (FGF21)
             related compounds
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:</last_name>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT# and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Arkansas Clinical Research</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kevin D Roberts, Site 0010</last_name>
      <phone>501-907-9170</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Anaheim Clinical Trials Llc</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amina Haggag, Site 0006</last_name>
      <phone>714-774-7777</phone>
      <phone_ext>Ext201</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Research Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Frias, Site 0013</last_name>
      <phone>213-413-2500</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Encompass Clinical Research</name>
      <address>
        <city>Spring Valley</city>
        <state>California</state>
        <zip>91978</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert S Lipetz, Site 0009</last_name>
      <phone>619-660-9068</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>All Medical Research, Llc</name>
      <address>
        <city>Cooper City</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorena Lewy-Alterbaum, Site 0012</last_name>
      <phone>754-263-2001</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Central Kentucky Research Associates, Inc.</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40509</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James L Borders, Site 0011</last_name>
      <phone>859-264-8999</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research Advantage, Inc./Skyline Medical Center</name>
      <address>
        <city>Elkhorn</city>
        <state>Nebraska</state>
        <zip>68022</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Fitzgibbons, Site 0015</last_name>
      <phone>402-614-5083</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Premier Research</name>
      <address>
        <city>Trenton</city>
        <state>New Jersey</state>
        <zip>08611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jane Rohlf, Site 0008</last_name>
      <phone>609-392-6666</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Metrolina Internal Medicine</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karlton Pettis, Site 0014</last_name>
      <phone>704-377-6906</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sterling Research Grp, Ltd.</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Wenker, Site 0007</last_name>
      <phone>513-381-4100</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <zip>L6T 0G1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0003</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Drummondville</city>
        <state>Quebec</state>
        <zip>J2B 7T1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0016</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2R 1V6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0005</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Victoriaville</city>
        <state>Quebec</state>
        <zip>G6P 6P6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0002</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Quebec</city>
        <zip>G3K 2P8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0001</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://ctr.bms.com/ctd/start.do</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 30, 2014</lastchanged_date>
  <firstreceived_date>March 19, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
